Bristol-Myers Squibb and Janssen Announce Nivolumab / Daratumumab Collaboration

Share this content:
Bristol-Myers Squibb and Janssen Biotech are collaborating to test whether combining nivolumab and daratumumab will have synergistic clinical effects.
Bristol-Myers Squibb and Janssen Biotech are collaborating to test whether combining nivolumab and daratumumab will have synergistic clinical effects.

Bristol-Myers Squibb and Janssen Biotech are collaborating to test whether combining nivolumab and daratumumab will have synergistic clinical effects, according to a press release.1

A phase 1 study (ClinicalTrials.gov Identifier: NCT01592370) of nivolumab in multiple myeloma will now include daratumumab in 1 of its study arms; more studies of the combination—in particular for solid tumors such as non-small cell lung cancer, colorectal cancer, triple-negative breast cancer, head and neck cancer, and pancreatic cancer—will commence in 2017.

RELATED: Multiple Myeloma: Adding Bortezomib to Lenalidomide, Dexamethasone as Front-line Treatment

Nivolumab is a PD-1 immune checkpoint inhibitor with several indications, including metastatic melanoma and non-small cell lung cancer. Daratumumab is a CD38-directed cytolytic antibody that is “believed to induce tumor cell death through multiple immune-mediated mechanisms of action and also demonstrates immunomodulatory activities by targeting immuno-suppressive cells in the tumor microenvironment.” It is indicated for some previously-treated patients with multiple myeloma.

The combination may be effective for a variety of cancers, though it is not specified how the drugs will work synergistically.

Reference

  1. Bristol-Myers Squibb announces immunotherapy clinical collaboration with Janssen to evaluate Opdivo (nivolumab) in combination with Darzalex (daratumumab). Bristol-Myers Squibb website. http://news.bms.com/press-release/partnering-news/bristol-myers-squibb-announces-immunotherapy-clinical-collaboration-ja. Published January 5, 2017. Accessed January 10, 2017.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters